Video

Dr. Tagawa on the growing role of radiopharmaceuticals in prostate cancer

“What I'm quite hopeful for are PSMA-targeted alpha emitters,” says Scott T. Tagawa, MD, MS, FACP.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Scott T. Tagawa, MD, MS, FACP, discusses ongoing and upcoming innovation in the radiopharmaceutical space for treatment of prostate cancer, as well as considerations for physicians who are administering these therapies. Tagawa is an associate professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      © 2025 MJH Life Sciences

      All rights reserved.